nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Tamoxifen—pancreatic cancer	0.239	0.464	CbGbCtD
Bosentan—ABCB11—Doxorubicin—pancreatic cancer	0.1	0.195	CbGbCtD
Bosentan—CYP2C9—Tamoxifen—pancreatic cancer	0.0423	0.082	CbGbCtD
Bosentan—ABCB11—bile duct—pancreatic cancer	0.0374	0.455	CbGeAlD
Bosentan—CYP2C9—Fluorouracil—pancreatic cancer	0.0312	0.0604	CbGbCtD
Bosentan—ABCB11—bile—pancreatic cancer	0.0287	0.35	CbGeAlD
Bosentan—CYP3A4—Tamoxifen—pancreatic cancer	0.0246	0.0477	CbGbCtD
Bosentan—CYP3A4—Erlotinib—pancreatic cancer	0.0209	0.0406	CbGbCtD
Bosentan—CYP3A4—Irinotecan—pancreatic cancer	0.0189	0.0366	CbGbCtD
Bosentan—CYP3A4—Docetaxel—pancreatic cancer	0.0138	0.0268	CbGbCtD
Bosentan—CYP3A4—Sunitinib—pancreatic cancer	0.0138	0.0267	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—pancreatic cancer	0.0103	0.02	CbGbCtD
Bosentan—EDNRB—islet of Langerhans—pancreatic cancer	0.00647	0.0788	CbGeAlD
Bosentan—EDNRB—pancreas—pancreatic cancer	0.00455	0.0554	CbGeAlD
Bosentan—ABCB11—digestive system—pancreatic cancer	0.00314	0.0382	CbGeAlD
Bosentan—CYP2C9—digestive system—pancreatic cancer	0.00106	0.0129	CbGeAlD
Bosentan—CYP3A4—digestive system—pancreatic cancer	0.00081	0.00987	CbGeAlD
Bosentan—Loss of consciousness—Docetaxel—pancreatic cancer	0.00017	0.000653	CcSEcCtD
Bosentan—Weight decreased—Epirubicin—pancreatic cancer	0.000169	0.000651	CcSEcCtD
Bosentan—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000169	0.000649	CcSEcCtD
Bosentan—Cough—Docetaxel—pancreatic cancer	0.000168	0.000648	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—pancreatic cancer	0.000168	0.000648	CcSEcCtD
Bosentan—Hypersensitivity—Irinotecan—pancreatic cancer	0.000168	0.000646	CcSEcCtD
Bosentan—Pneumonia—Epirubicin—pancreatic cancer	0.000168	0.000645	CcSEcCtD
Bosentan—Infestation—Epirubicin—pancreatic cancer	0.000167	0.000641	CcSEcCtD
Bosentan—Infestation NOS—Epirubicin—pancreatic cancer	0.000167	0.000641	CcSEcCtD
Bosentan—Bronchitis—Doxorubicin—pancreatic cancer	0.000166	0.00064	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000165	0.000636	CcSEcCtD
Bosentan—Chest pain—Docetaxel—pancreatic cancer	0.000164	0.000633	CcSEcCtD
Bosentan—Arthralgia—Docetaxel—pancreatic cancer	0.000164	0.000633	CcSEcCtD
Bosentan—Nausea—Sunitinib—pancreatic cancer	0.000164	0.000633	CcSEcCtD
Bosentan—Renal failure—Epirubicin—pancreatic cancer	0.000164	0.00063	CcSEcCtD
Bosentan—Asthenia—Irinotecan—pancreatic cancer	0.000163	0.000629	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000163	0.000628	CcSEcCtD
Bosentan—Jaundice—Epirubicin—pancreatic cancer	0.000162	0.000625	CcSEcCtD
Bosentan—Stomatitis—Epirubicin—pancreatic cancer	0.000162	0.000625	CcSEcCtD
Bosentan—Urinary tract infection—Epirubicin—pancreatic cancer	0.000162	0.000623	CcSEcCtD
Bosentan—Conjunctivitis—Epirubicin—pancreatic cancer	0.000162	0.000623	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—pancreatic cancer	0.000162	0.000622	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—pancreatic cancer	0.000162	0.000622	CcSEcCtD
Bosentan—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000161	0.000619	CcSEcCtD
Bosentan—Dry mouth—Docetaxel—pancreatic cancer	0.000161	0.000619	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000161	0.000619	CcSEcCtD
Bosentan—Pollakiuria—Doxorubicin—pancreatic cancer	0.00016	0.000615	CcSEcCtD
Bosentan—Asthenia—Gemcitabine—pancreatic cancer	0.000159	0.000613	CcSEcCtD
Bosentan—Haematuria—Epirubicin—pancreatic cancer	0.000159	0.000612	CcSEcCtD
Bosentan—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000158	0.000607	CcSEcCtD
Bosentan—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000158	0.000606	CcSEcCtD
Bosentan—Oedema—Docetaxel—pancreatic cancer	0.000158	0.000606	CcSEcCtD
Bosentan—Weight increased—Doxorubicin—pancreatic cancer	0.000157	0.000606	CcSEcCtD
Bosentan—Epistaxis—Epirubicin—pancreatic cancer	0.000157	0.000605	CcSEcCtD
Bosentan—Pruritus—Gemcitabine—pancreatic cancer	0.000157	0.000605	CcSEcCtD
Bosentan—Infection—Docetaxel—pancreatic cancer	0.000156	0.000602	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—pancreatic cancer	0.000156	0.000602	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—pancreatic cancer	0.000156	0.000602	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000156	0.0006	CcSEcCtD
Bosentan—Diarrhoea—Irinotecan—pancreatic cancer	0.000156	0.0006	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—pancreatic cancer	0.000155	0.000597	CcSEcCtD
Bosentan—Shock—Docetaxel—pancreatic cancer	0.000155	0.000597	CcSEcCtD
Bosentan—Nervous system disorder—Docetaxel—pancreatic cancer	0.000154	0.000595	CcSEcCtD
Bosentan—Pruritus—Fluorouracil—pancreatic cancer	0.000154	0.000594	CcSEcCtD
Bosentan—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000154	0.000594	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—pancreatic cancer	0.000154	0.000593	CcSEcCtD
Bosentan—Infestation—Doxorubicin—pancreatic cancer	0.000154	0.000593	CcSEcCtD
Bosentan—Tachycardia—Docetaxel—pancreatic cancer	0.000154	0.000592	CcSEcCtD
Bosentan—Skin disorder—Docetaxel—pancreatic cancer	0.000153	0.000589	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000153	0.000588	CcSEcCtD
Bosentan—Bradycardia—Epirubicin—pancreatic cancer	0.000152	0.000586	CcSEcCtD
Bosentan—Diarrhoea—Gemcitabine—pancreatic cancer	0.000152	0.000585	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—pancreatic cancer	0.000152	0.000583	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—ACVR1B—pancreatic cancer	0.000151	0.00106	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ZNRF3—pancreatic cancer	0.000151	0.00106	CbGpPWpGaD
Bosentan—Dizziness—Irinotecan—pancreatic cancer	0.000151	0.00058	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—pancreatic cancer	0.00015	0.000579	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—pancreatic cancer	0.00015	0.000578	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—pancreatic cancer	0.00015	0.000578	CcSEcCtD
Bosentan—Anorexia—Docetaxel—pancreatic cancer	0.00015	0.000578	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00015	0.000577	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—pancreatic cancer	0.00015	0.000577	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—HEY2—pancreatic cancer	0.00015	0.00105	CbGpPWpGaD
Bosentan—Haemorrhage—Epirubicin—pancreatic cancer	0.00015	0.000576	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—pancreatic cancer	0.00015	0.000576	CcSEcCtD
Bosentan—Diarrhoea—Fluorouracil—pancreatic cancer	0.000149	0.000575	CcSEcCtD
Bosentan—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000149	0.000573	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000148	0.000569	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—pancreatic cancer	0.000147	0.000567	CcSEcCtD
Bosentan—Hypotension—Docetaxel—pancreatic cancer	0.000147	0.000567	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—pancreatic cancer	0.000147	0.000566	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—pancreatic cancer	0.000147	0.000564	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GAST—pancreatic cancer	0.000146	0.00102	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000146	0.00102	CbGpPWpGaD
Bosentan—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000146	0.000561	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—pancreatic cancer	0.000145	0.00056	CcSEcCtD
Bosentan—Vomiting—Irinotecan—pancreatic cancer	0.000145	0.000558	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000145	0.00101	CbGpPWpGaD
Bosentan—Sinusitis—Doxorubicin—pancreatic cancer	0.000145	0.000557	CcSEcCtD
Bosentan—Dizziness—Fluorouracil—pancreatic cancer	0.000144	0.000556	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—AGTR1—pancreatic cancer	0.000144	0.00101	CbGpPWpGaD
Bosentan—Rash—Irinotecan—pancreatic cancer	0.000144	0.000553	CcSEcCtD
Bosentan—Dermatitis—Irinotecan—pancreatic cancer	0.000144	0.000553	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000144	0.000553	CcSEcCtD
Bosentan—Headache—Irinotecan—pancreatic cancer	0.000143	0.00055	CcSEcCtD
Bosentan—Insomnia—Docetaxel—pancreatic cancer	0.000142	0.000549	CcSEcCtD
Bosentan—Paraesthesia—Docetaxel—pancreatic cancer	0.000141	0.000545	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—pancreatic cancer	0.000141	0.000544	CcSEcCtD
Bosentan—Vomiting—Gemcitabine—pancreatic cancer	0.000141	0.000543	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—pancreatic cancer	0.000141	0.000542	CcSEcCtD
Bosentan—Dyspnoea—Docetaxel—pancreatic cancer	0.00014	0.000541	CcSEcCtD
Bosentan—Somnolence—Docetaxel—pancreatic cancer	0.00014	0.000539	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—SHH—pancreatic cancer	0.00014	0.000981	CbGpPWpGaD
Bosentan—Rash—Gemcitabine—pancreatic cancer	0.00014	0.000539	CcSEcCtD
Bosentan—Dermatitis—Gemcitabine—pancreatic cancer	0.00014	0.000538	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—pancreatic cancer	0.00014	0.000538	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—pancreatic cancer	0.000139	0.000537	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—pancreatic cancer	0.000139	0.000535	CcSEcCtD
Bosentan—Headache—Gemcitabine—pancreatic cancer	0.000139	0.000535	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—pancreatic cancer	0.000139	0.000534	CcSEcCtD
Bosentan—Flushing—Epirubicin—pancreatic cancer	0.000139	0.000534	CcSEcCtD
Bosentan—Vomiting—Fluorouracil—pancreatic cancer	0.000139	0.000534	CcSEcCtD
Bosentan—Dyspepsia—Docetaxel—pancreatic cancer	0.000139	0.000534	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—SCT—pancreatic cancer	0.000139	0.000971	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HEY1—pancreatic cancer	0.000139	0.000971	CbGpPWpGaD
Bosentan—Hepatitis—Doxorubicin—pancreatic cancer	0.000138	0.000533	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—pancreatic cancer	0.000138	0.000533	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—IAPP—pancreatic cancer	0.000138	0.000969	CbGpPWpGaD
Bosentan—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000138	0.00053	CcSEcCtD
Bosentan—Rash—Fluorouracil—pancreatic cancer	0.000138	0.00053	CcSEcCtD
Bosentan—Dermatitis—Fluorouracil—pancreatic cancer	0.000137	0.000529	CcSEcCtD
Bosentan—Decreased appetite—Docetaxel—pancreatic cancer	0.000137	0.000527	CcSEcCtD
Bosentan—Headache—Fluorouracil—pancreatic cancer	0.000137	0.000526	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000137	0.000526	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—DTX1—pancreatic cancer	0.000136	0.000956	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SSTR3—pancreatic cancer	0.000136	0.000956	CbGpPWpGaD
Bosentan—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000136	0.000525	CcSEcCtD
Bosentan—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000136	0.000524	CcSEcCtD
Bosentan—Fatigue—Docetaxel—pancreatic cancer	0.000136	0.000523	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—pancreatic cancer	0.000136	0.000522	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—pancreatic cancer	0.000136	0.000522	CcSEcCtD
Bosentan—Nausea—Irinotecan—pancreatic cancer	0.000135	0.000521	CcSEcCtD
Bosentan—Immune system disorder—Epirubicin—pancreatic cancer	0.000135	0.00052	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000135	0.000519	CcSEcCtD
Bosentan—Constipation—Docetaxel—pancreatic cancer	0.000135	0.000519	CcSEcCtD
Bosentan—Pain—Docetaxel—pancreatic cancer	0.000135	0.000519	CcSEcCtD
Bosentan—Chills—Epirubicin—pancreatic cancer	0.000134	0.000517	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000134	0.000939	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—SST—pancreatic cancer	0.000134	0.000936	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000133	0.000931	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PTCH1—pancreatic cancer	0.000133	0.00093	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PTHLH—pancreatic cancer	0.000133	0.00093	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCK—pancreatic cancer	0.000132	0.000926	CbGpPWpGaD
Bosentan—Nausea—Gemcitabine—pancreatic cancer	0.000132	0.000508	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000131	0.000918	CbGpPWpGaD
Bosentan—Mental disorder—Epirubicin—pancreatic cancer	0.000131	0.000504	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—SSTR1—pancreatic cancer	0.000131	0.000917	CbGpPWpGaD
Bosentan—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000131	0.000504	CcSEcCtD
Bosentan—Erythema—Epirubicin—pancreatic cancer	0.00013	0.000501	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—pancreatic cancer	0.00013	0.000501	CcSEcCtD
Bosentan—Nausea—Fluorouracil—pancreatic cancer	0.00013	0.000499	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—pancreatic cancer	0.000129	0.000498	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—pancreatic cancer	0.000129	0.000497	CcSEcCtD
Bosentan—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000129	0.000496	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GLP1R—pancreatic cancer	0.000129	0.000903	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CNR2—pancreatic cancer	0.000129	0.000903	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CXCL8—pancreatic cancer	0.000129	0.000902	CbGpPWpGaD
Bosentan—Flushing—Doxorubicin—pancreatic cancer	0.000128	0.000494	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000128	0.000494	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PPY—pancreatic cancer	0.000128	0.000899	CbGpPWpGaD
Bosentan—Flatulence—Epirubicin—pancreatic cancer	0.000128	0.000494	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CCKAR—pancreatic cancer	0.000127	0.000888	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SSTR2—pancreatic cancer	0.000126	0.000883	CbGpPWpGaD
Bosentan—Back pain—Epirubicin—pancreatic cancer	0.000126	0.000485	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—pancreatic cancer	0.000126	0.000483	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—pancreatic cancer	0.000125	0.000482	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—pancreatic cancer	0.000125	0.000481	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000125	0.00048	CcSEcCtD
Bosentan—Body temperature increased—Docetaxel—pancreatic cancer	0.000125	0.000479	CcSEcCtD
Bosentan—Abdominal pain—Docetaxel—pancreatic cancer	0.000125	0.000479	CcSEcCtD
Bosentan—Chills—Doxorubicin—pancreatic cancer	0.000124	0.000478	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—CNR1—pancreatic cancer	0.000123	0.000864	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JAG2—pancreatic cancer	0.000123	0.000861	CbGpPWpGaD
Bosentan—Vision blurred—Epirubicin—pancreatic cancer	0.000123	0.000472	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CCKBR—pancreatic cancer	0.000122	0.000852	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—SST—pancreatic cancer	0.000121	0.00085	CbGpPWpGaD
Bosentan—Mental disorder—Doxorubicin—pancreatic cancer	0.000121	0.000467	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—MEN1—pancreatic cancer	0.000121	0.000849	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000121	0.000848	CbGpPWpGaD
Bosentan—Erythema—Doxorubicin—pancreatic cancer	0.00012	0.000464	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—pancreatic cancer	0.00012	0.000464	CcSEcCtD
Bosentan—Anaemia—Epirubicin—pancreatic cancer	0.00012	0.000463	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000119	0.000837	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—GCG—pancreatic cancer	0.000119	0.000835	CbGpPWpGaD
Bosentan—Flatulence—Doxorubicin—pancreatic cancer	0.000119	0.000457	CcSEcCtD
Bosentan—Vertigo—Epirubicin—pancreatic cancer	0.000117	0.00045	CcSEcCtD
Bosentan—Syncope—Epirubicin—pancreatic cancer	0.000117	0.000449	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—pancreatic cancer	0.000117	0.000449	CcSEcCtD
Bosentan—Back pain—Doxorubicin—pancreatic cancer	0.000117	0.000449	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—pancreatic cancer	0.000116	0.000816	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PRSS1—pancreatic cancer	0.000116	0.000815	CbGpPWpGaD
Bosentan—Hypersensitivity—Docetaxel—pancreatic cancer	0.000116	0.000447	CcSEcCtD
Bosentan—EDNRA—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000116	0.000812	CbGpPWpGaD
Bosentan—Muscle spasms—Doxorubicin—pancreatic cancer	0.000116	0.000446	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—SHH—pancreatic cancer	0.000116	0.00081	CbGpPWpGaD
Bosentan—Palpitations—Epirubicin—pancreatic cancer	0.000115	0.000443	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—NOTCH4—pancreatic cancer	0.000115	0.000804	CbGpPWpGaD
Bosentan—Loss of consciousness—Epirubicin—pancreatic cancer	0.000114	0.000441	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—DTX4—pancreatic cancer	0.000114	0.000801	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GLI1—pancreatic cancer	0.000114	0.000801	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IAPP—pancreatic cancer	0.000114	0.0008	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000114	0.000796	CbGpPWpGaD
Bosentan—Cough—Epirubicin—pancreatic cancer	0.000114	0.000437	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—pancreatic cancer	0.000114	0.000437	CcSEcCtD
Bosentan—Asthenia—Docetaxel—pancreatic cancer	0.000113	0.000435	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000113	0.000791	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CNR1—pancreatic cancer	0.000112	0.000785	CbGpPWpGaD
Bosentan—Pruritus—Docetaxel—pancreatic cancer	0.000111	0.000429	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—pancreatic cancer	0.000111	0.000429	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000111	0.00078	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRP1—pancreatic cancer	0.000111	0.00078	CbGpPWpGaD
Bosentan—Chest pain—Epirubicin—pancreatic cancer	0.000111	0.000427	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—pancreatic cancer	0.000111	0.000427	CcSEcCtD
Bosentan—Anxiety—Epirubicin—pancreatic cancer	0.00011	0.000425	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00011	0.000424	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PTHLH—pancreatic cancer	0.00011	0.000767	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTCH1—pancreatic cancer	0.00011	0.000767	CbGpPWpGaD
Bosentan—Discomfort—Epirubicin—pancreatic cancer	0.00011	0.000422	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—pancreatic cancer	0.000108	0.000417	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—pancreatic cancer	0.000108	0.000417	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—GCG—pancreatic cancer	0.000108	0.000758	CbGpPWpGaD
Bosentan—Syncope—Doxorubicin—pancreatic cancer	0.000108	0.000416	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—pancreatic cancer	0.000108	0.000415	CcSEcCtD
Bosentan—Diarrhoea—Docetaxel—pancreatic cancer	0.000108	0.000415	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—HEY2—pancreatic cancer	0.000107	0.00075	CbGpPWpGaD
Bosentan—Palpitations—Doxorubicin—pancreatic cancer	0.000106	0.00041	CcSEcCtD
Bosentan—Oedema—Epirubicin—pancreatic cancer	0.000106	0.000409	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000106	0.000409	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000106	0.000408	CcSEcCtD
Bosentan—Infection—Epirubicin—pancreatic cancer	0.000106	0.000406	CcSEcCtD
Bosentan—Cough—Doxorubicin—pancreatic cancer	0.000105	0.000405	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—GAST—pancreatic cancer	0.000105	0.000733	CbGpPWpGaD
Bosentan—Shock—Epirubicin—pancreatic cancer	0.000105	0.000402	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—pancreatic cancer	0.000104	0.000401	CcSEcCtD
Bosentan—Dizziness—Docetaxel—pancreatic cancer	0.000104	0.000401	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000104	0.000401	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—pancreatic cancer	0.000104	0.000399	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000104	0.000726	CbGpPWpGaD
Bosentan—Skin disorder—Epirubicin—pancreatic cancer	0.000103	0.000397	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—AGTR1—pancreatic cancer	0.000103	0.000723	CbGpPWpGaD
Bosentan—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000103	0.000395	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—pancreatic cancer	0.000103	0.000395	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—pancreatic cancer	0.000103	0.000395	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—pancreatic cancer	0.000102	0.000393	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000102	0.000392	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—pancreatic cancer	0.000101	0.00039	CcSEcCtD
Bosentan—Anorexia—Epirubicin—pancreatic cancer	0.000101	0.00039	CcSEcCtD
Bosentan—ABCB11—Metabolism—ARG2—pancreatic cancer	0.000101	0.000707	CbGpPWpGaD
Bosentan—Dry mouth—Doxorubicin—pancreatic cancer	0.0001	0.000386	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—SST—pancreatic cancer	0.0001	0.000702	CbGpPWpGaD
Bosentan—Vomiting—Docetaxel—pancreatic cancer	0.0001	0.000386	CcSEcCtD
Bosentan—Rash—Docetaxel—pancreatic cancer	9.93e-05	0.000382	CcSEcCtD
Bosentan—Hypotension—Epirubicin—pancreatic cancer	9.93e-05	0.000382	CcSEcCtD
Bosentan—Dermatitis—Docetaxel—pancreatic cancer	9.92e-05	0.000382	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—SCT—pancreatic cancer	9.92e-05	0.000695	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HEY1—pancreatic cancer	9.92e-05	0.000695	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.88e-05	0.000692	CbGpPWpGaD
Bosentan—Headache—Docetaxel—pancreatic cancer	9.87e-05	0.00038	CcSEcCtD
Bosentan—Oedema—Doxorubicin—pancreatic cancer	9.83e-05	0.000378	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—pancreatic cancer	9.83e-05	0.000378	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—JAG1—pancreatic cancer	9.8e-05	0.000687	CbGpPWpGaD
Bosentan—Infection—Doxorubicin—pancreatic cancer	9.77e-05	0.000376	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—NOTCH3—pancreatic cancer	9.76e-05	0.000684	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	9.68e-05	0.000373	CcSEcCtD
Bosentan—Shock—Doxorubicin—pancreatic cancer	9.67e-05	0.000372	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—pancreatic cancer	9.64e-05	0.000371	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—pancreatic cancer	9.63e-05	0.000371	CcSEcCtD
Bosentan—Insomnia—Epirubicin—pancreatic cancer	9.61e-05	0.00037	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—pancreatic cancer	9.59e-05	0.000369	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	9.59e-05	0.000672	CbGpPWpGaD
Bosentan—Skin disorder—Doxorubicin—pancreatic cancer	9.55e-05	0.000368	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—pancreatic cancer	9.54e-05	0.000367	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—pancreatic cancer	9.5e-05	0.000366	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—pancreatic cancer	9.47e-05	0.000365	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CCK—pancreatic cancer	9.46e-05	0.000663	CbGpPWpGaD
Bosentan—Somnolence—Epirubicin—pancreatic cancer	9.45e-05	0.000364	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—pancreatic cancer	9.37e-05	0.000361	CcSEcCtD
Bosentan—Nausea—Docetaxel—pancreatic cancer	9.36e-05	0.00036	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—pancreatic cancer	9.35e-05	0.00036	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CNR1—pancreatic cancer	9.24e-05	0.000648	CbGpPWpGaD
Bosentan—Decreased appetite—Epirubicin—pancreatic cancer	9.24e-05	0.000356	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CNR2—pancreatic cancer	9.22e-05	0.000646	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GLP1R—pancreatic cancer	9.22e-05	0.000646	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL8—pancreatic cancer	9.21e-05	0.000646	CbGpPWpGaD
Bosentan—Hypotension—Doxorubicin—pancreatic cancer	9.19e-05	0.000354	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.17e-05	0.000353	CcSEcCtD
Bosentan—Fatigue—Epirubicin—pancreatic cancer	9.16e-05	0.000353	CcSEcCtD
Bosentan—Constipation—Epirubicin—pancreatic cancer	9.09e-05	0.00035	CcSEcCtD
Bosentan—Pain—Epirubicin—pancreatic cancer	9.09e-05	0.00035	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CCKAR—pancreatic cancer	9.07e-05	0.000636	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CG—pancreatic cancer	8.97e-05	0.000629	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	8.96e-05	0.000345	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GCG—pancreatic cancer	8.93e-05	0.000626	CbGpPWpGaD
Bosentan—Insomnia—Doxorubicin—pancreatic cancer	8.89e-05	0.000342	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—pancreatic cancer	8.83e-05	0.00034	CcSEcCtD
Bosentan—ABCB11—Metabolism—TYMP—pancreatic cancer	8.81e-05	0.000618	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JAG2—pancreatic cancer	8.79e-05	0.000616	CbGpPWpGaD
Bosentan—Dyspnoea—Doxorubicin—pancreatic cancer	8.76e-05	0.000337	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—pancreatic cancer	8.74e-05	0.000336	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—pancreatic cancer	8.69e-05	0.000334	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.69e-05	0.000609	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MEN1—pancreatic cancer	8.67e-05	0.000607	CbGpPWpGaD
Bosentan—Dyspepsia—Doxorubicin—pancreatic cancer	8.65e-05	0.000333	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—pancreatic cancer	8.55e-05	0.000329	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—AGTR1—pancreatic cancer	8.52e-05	0.000597	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.49e-05	0.000327	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—pancreatic cancer	8.48e-05	0.000326	CcSEcCtD
Bosentan—Urticaria—Epirubicin—pancreatic cancer	8.44e-05	0.000325	CcSEcCtD
Bosentan—Pain—Doxorubicin—pancreatic cancer	8.41e-05	0.000324	CcSEcCtD
Bosentan—Constipation—Doxorubicin—pancreatic cancer	8.41e-05	0.000324	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—pancreatic cancer	8.4e-05	0.000323	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—pancreatic cancer	8.4e-05	0.000323	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—STK11—pancreatic cancer	8.39e-05	0.000588	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SHH—pancreatic cancer	8.27e-05	0.000579	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH4—pancreatic cancer	8.22e-05	0.000576	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IAPP—pancreatic cancer	8.17e-05	0.000572	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.04e-05	0.000309	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PIK3CD—pancreatic cancer	7.89e-05	0.000553	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTHLH—pancreatic cancer	7.84e-05	0.000549	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTCH1—pancreatic cancer	7.84e-05	0.000549	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—pancreatic cancer	7.83e-05	0.000301	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—pancreatic cancer	7.81e-05	0.000301	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—pancreatic cancer	7.77e-05	0.000299	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—pancreatic cancer	7.77e-05	0.000299	CcSEcCtD
Bosentan—Asthenia—Epirubicin—pancreatic cancer	7.62e-05	0.000293	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.57e-05	0.00053	CbGpPWpGaD
Bosentan—Pruritus—Epirubicin—pancreatic cancer	7.52e-05	0.000289	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—SMAD4—pancreatic cancer	7.35e-05	0.000515	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCL8—pancreatic cancer	7.27e-05	0.00051	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.27e-05	0.00051	CbGpPWpGaD
Bosentan—Diarrhoea—Epirubicin—pancreatic cancer	7.27e-05	0.00028	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—pancreatic cancer	7.24e-05	0.000279	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—HES1—pancreatic cancer	7.18e-05	0.000503	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SST—pancreatic cancer	7.17e-05	0.000502	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GLP1R—pancreatic cancer	7.1e-05	0.000498	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.07e-05	0.000495	CbGpPWpGaD
Bosentan—Asthenia—Doxorubicin—pancreatic cancer	7.05e-05	0.000272	CcSEcCtD
Bosentan—Dizziness—Epirubicin—pancreatic cancer	7.03e-05	0.00027	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—JAG1—pancreatic cancer	7.02e-05	0.000492	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—DPYD—pancreatic cancer	6.99e-05	0.00049	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH3—pancreatic cancer	6.99e-05	0.00049	CbGpPWpGaD
Bosentan—Pruritus—Doxorubicin—pancreatic cancer	6.96e-05	0.000268	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PIK3CB—pancreatic cancer	6.87e-05	0.000482	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—pancreatic cancer	6.76e-05	0.00026	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—pancreatic cancer	6.73e-05	0.000259	CcSEcCtD
Bosentan—Rash—Epirubicin—pancreatic cancer	6.7e-05	0.000258	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—pancreatic cancer	6.69e-05	0.000258	CcSEcCtD
Bosentan—Headache—Epirubicin—pancreatic cancer	6.66e-05	0.000256	CcSEcCtD
Bosentan—ABCB11—Metabolism—SLC2A2—pancreatic cancer	6.63e-05	0.000465	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CNR1—pancreatic cancer	6.62e-05	0.000464	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCL8—pancreatic cancer	6.61e-05	0.000463	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.56e-05	0.00046	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—pancreatic cancer	6.5e-05	0.00025	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—PIK3CG—pancreatic cancer	6.42e-05	0.00045	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GCG—pancreatic cancer	6.39e-05	0.000448	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.34e-05	0.000444	CbGpPWpGaD
Bosentan—Nausea—Epirubicin—pancreatic cancer	6.31e-05	0.000243	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TERT—pancreatic cancer	6.29e-05	0.000441	CbGpPWpGaD
Bosentan—Vomiting—Doxorubicin—pancreatic cancer	6.25e-05	0.000241	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.22e-05	0.000436	CbGpPWpGaD
Bosentan—Rash—Doxorubicin—pancreatic cancer	6.2e-05	0.000239	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—pancreatic cancer	6.19e-05	0.000238	CcSEcCtD
Bosentan—Headache—Doxorubicin—pancreatic cancer	6.16e-05	0.000237	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—AGTR1—pancreatic cancer	6.1e-05	0.000427	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HIF1A—pancreatic cancer	6.02e-05	0.000422	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STK11—pancreatic cancer	6.01e-05	0.000421	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TSC2—pancreatic cancer	6e-05	0.000421	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—APOE—pancreatic cancer	5.87e-05	0.000412	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—pancreatic cancer	5.84e-05	0.000225	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.77e-05	0.000404	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KDR—pancreatic cancer	5.75e-05	0.000403	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CD—pancreatic cancer	5.64e-05	0.000396	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NFKBIA—pancreatic cancer	5.47e-05	0.000383	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NOTCH1—pancreatic cancer	5.42e-05	0.00038	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.42e-05	0.00038	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CG—pancreatic cancer	5.3e-05	0.000371	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—NRAS—pancreatic cancer	5.3e-05	0.000371	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SMAD4—pancreatic cancer	5.26e-05	0.000369	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGF—pancreatic cancer	5.24e-05	0.000367	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL8—pancreatic cancer	5.21e-05	0.000365	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HES1—pancreatic cancer	5.14e-05	0.00036	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CD44—pancreatic cancer	5.14e-05	0.00036	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.03e-05	0.000352	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.98e-05	0.000349	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GCG—pancreatic cancer	4.92e-05	0.000345	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CB—pancreatic cancer	4.92e-05	0.000345	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—pancreatic cancer	4.83e-05	0.000338	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL8—pancreatic cancer	4.73e-05	0.000331	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CD—pancreatic cancer	4.66e-05	0.000326	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—STK11—pancreatic cancer	4.63e-05	0.000324	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.61e-05	0.000323	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KRAS—pancreatic cancer	4.56e-05	0.00032	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TERT—pancreatic cancer	4.5e-05	0.000315	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.35e-05	0.000305	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HIF1A—pancreatic cancer	4.31e-05	0.000302	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TSC2—pancreatic cancer	4.29e-05	0.000301	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—APOE—pancreatic cancer	4.2e-05	0.000295	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—pancreatic cancer	4.19e-05	0.000294	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KDR—pancreatic cancer	4.12e-05	0.000289	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CB—pancreatic cancer	4.06e-05	0.000285	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TYMS—pancreatic cancer	3.98e-05	0.000279	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NFKBIA—pancreatic cancer	3.92e-05	0.000274	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL8—pancreatic cancer	3.9e-05	0.000273	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PRSS1—pancreatic cancer	3.88e-05	0.000272	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH1—pancreatic cancer	3.88e-05	0.000272	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—pancreatic cancer	3.88e-05	0.000272	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CG—pancreatic cancer	3.79e-05	0.000266	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NRAS—pancreatic cancer	3.79e-05	0.000266	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—pancreatic cancer	3.77e-05	0.000264	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGF—pancreatic cancer	3.75e-05	0.000263	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CASP3—pancreatic cancer	3.74e-05	0.000262	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—pancreatic cancer	3.64e-05	0.000255	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNB1—pancreatic cancer	3.6e-05	0.000252	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—pancreatic cancer	3.53e-05	0.000247	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—pancreatic cancer	3.51e-05	0.000246	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—pancreatic cancer	3.46e-05	0.000242	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—pancreatic cancer	3.42e-05	0.00024	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ARG2—pancreatic cancer	3.37e-05	0.000236	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CD—pancreatic cancer	3.33e-05	0.000234	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.3e-05	0.000231	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—pancreatic cancer	3.26e-05	0.000229	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SRC—pancreatic cancer	3.25e-05	0.000228	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—APOE—pancreatic cancer	3.24e-05	0.000227	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—pancreatic cancer	3.17e-05	0.000222	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT3—pancreatic cancer	3.14e-05	0.00022	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRAS—pancreatic cancer	3.13e-05	0.000219	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.07e-05	0.000215	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—pancreatic cancer	3e-05	0.00021	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMP—pancreatic cancer	2.94e-05	0.000206	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CG—pancreatic cancer	2.92e-05	0.000205	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—pancreatic cancer	2.92e-05	0.000204	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFB1—pancreatic cancer	2.91e-05	0.000204	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CB—pancreatic cancer	2.91e-05	0.000204	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—pancreatic cancer	2.85e-05	0.0002	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPARG—pancreatic cancer	2.82e-05	0.000198	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL8—pancreatic cancer	2.79e-05	0.000196	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—pancreatic cancer	2.77e-05	0.000194	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—pancreatic cancer	2.7e-05	0.000189	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—pancreatic cancer	2.69e-05	0.000189	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—pancreatic cancer	2.67e-05	0.000187	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—pancreatic cancer	2.6e-05	0.000182	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNB1—pancreatic cancer	2.58e-05	0.000181	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CD—pancreatic cancer	2.57e-05	0.00018	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PRSS1—pancreatic cancer	2.56e-05	0.000179	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—pancreatic cancer	2.53e-05	0.000177	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—pancreatic cancer	2.51e-05	0.000176	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—pancreatic cancer	2.48e-05	0.000173	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—pancreatic cancer	2.45e-05	0.000172	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.43e-05	0.00017	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—pancreatic cancer	2.39e-05	0.000168	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GLP1R—pancreatic cancer	2.37e-05	0.000166	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DPYD—pancreatic cancer	2.33e-05	0.000164	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SRC—pancreatic cancer	2.33e-05	0.000163	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—pancreatic cancer	2.29e-05	0.00016	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—pancreatic cancer	2.27e-05	0.000159	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—pancreatic cancer	2.25e-05	0.000157	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRAS—pancreatic cancer	2.24e-05	0.000157	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CB—pancreatic cancer	2.24e-05	0.000157	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ARG2—pancreatic cancer	2.22e-05	0.000156	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—pancreatic cancer	2.22e-05	0.000156	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	2.21e-05	0.000155	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.19e-05	0.000154	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.12e-05	0.000148	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—pancreatic cancer	2.09e-05	0.000146	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—pancreatic cancer	2.08e-05	0.000146	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—pancreatic cancer	2.04e-05	0.000143	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—pancreatic cancer	2.02e-05	0.000142	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.94e-05	0.000136	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—pancreatic cancer	1.94e-05	0.000136	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—pancreatic cancer	1.93e-05	0.000135	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.93e-05	0.000135	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—pancreatic cancer	1.77e-05	0.000124	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CD44—pancreatic cancer	1.71e-05	0.00012	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—pancreatic cancer	1.71e-05	0.00012	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.68e-05	0.000118	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.66e-05	0.000117	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GCG—pancreatic cancer	1.64e-05	0.000115	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—pancreatic cancer	1.64e-05	0.000115	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.56e-05	0.00011	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—STK11—pancreatic cancer	1.55e-05	0.000108	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.54e-05	0.000108	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.46e-05	0.000102	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.45e-05	0.000102	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—pancreatic cancer	1.45e-05	0.000101	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—pancreatic cancer	1.37e-05	9.57e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMS—pancreatic cancer	1.33e-05	9.32e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CD44—pancreatic cancer	1.13e-05	7.92e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—pancreatic cancer	1.12e-05	7.82e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GCG—pancreatic cancer	1.08e-05	7.6e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—APOE—pancreatic cancer	1.08e-05	7.58e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.02e-05	7.17e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—STK11—pancreatic cancer	1.02e-05	7.14e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	9.76e-06	6.84e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPARG—pancreatic cancer	9.42e-06	6.6e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMS—pancreatic cancer	8.77e-06	6.14e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	8.58e-06	6.01e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	7.48e-06	5.24e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—pancreatic cancer	7.41e-06	5.19e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—APOE—pancreatic cancer	7.13e-06	5e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—pancreatic cancer	6.46e-06	4.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	6.44e-06	4.51e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPARG—pancreatic cancer	6.21e-06	4.35e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	5.66e-06	3.96e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	4.93e-06	3.46e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—pancreatic cancer	4.89e-06	3.42e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	4.56e-06	3.19e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—pancreatic cancer	4.26e-06	2.99e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—pancreatic cancer	3.72e-06	2.61e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.01e-06	2.11e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.46e-06	1.72e-05	CbGpPWpGaD
